Notice for migalastat (Amicus Therapeutics Pty Ltd)
Active ingredients
migalastat
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Hard capsule
Indication
Indicated for long-term treatment of adult and adolescent patients 12 years and older with a confirmed diagnosis of Fabry disease (α ;-galactosidase A deficiency) and who have an amenable mutation.
Therapeutic area
Inherited metabolic disorders